Patents by Inventor Baomei Wang

Baomei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods of Chimeric Autoantibody Receptor Cells Expressing Extended Phospholipase A2 Receptor Fragments
    Publication number: 20250073265
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells (e.g., T cells) comprising the CAAR, wherein the CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7). The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7).
    Type: Application
    Filed: August 4, 2022
    Publication date: March 6, 2025
    Inventors: Aimee S. Payne, Baomei Wang
  • COMPOSITIONS AND METHODS OF PHOSPHOLIPASE A2 RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20240383965
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
    Type: Application
    Filed: April 19, 2024
    Publication date: November 21, 2024
    Inventors: Saar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang
  • MULTISPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20240360229
    Abstract: The present invention provides anti-C-C motif chemokine receptor 8 (CCR8) antigen-binding molecules (e.g., bispecific antigen-binding molecules) and compositions thereof. The invention also features polynucleotides, vectors, host cells, methods of production, pharmaceutical compositions, methods of treating a disease or disorder, such as cancer, methods of depleting regulatory T cells, related uses and compositions for use, and kits for use with the one or more methods.
    Type: Application
    Filed: January 18, 2024
    Publication date: October 31, 2024
    Inventors: Christoph SPIESS, Baomei WANG, Ambrose Jon WILLIAMS, Cecilia Pui Chi CHIU, Michael Andrew DILLON, Teemu Tapani JUNTTILA, James Thomas KOERBER
  • Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells
    Patent number: 11884716
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Saar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang
  • COMPOSITIONS AND METHODS OF PHOSPHOLIPASE A2 RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20220098271
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 31, 2022
    Inventors: Saar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang
  • COMPOSITIONS AND METHODS OF PHOSPHOLIPASE A2 RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20210095001
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
    Type: Application
    Filed: May 2, 2019
    Publication date: April 1, 2021
    Inventors: Saar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang